Theratechnologies Secures US Patent for its Novel Peptide TH1173
January 29 2013 - 9:55AM
Marketwired
Theratechnologies Inc. (TSX:TH)(NASDAQ:THER) today reported that
the US Patent and Trademark Office (USPTO) has granted a patent (US
Patent No. 8,361,964) for its second generation growth-hormone
releasing factor (GRF) peptide, TH1173, providing for patent
protection beyond 2030.
"While we are currently focusing all of our efforts and
resources on revenue growth from tesamorelin as per our revised
business plan, we still firmly believe in the long-term potential
of TH1173. With this patent in place, we now have a secure
timeframe during which we will be able to explore partnerships and
licensing activities in certain territories to tap into this
potential in the future," stated Luc Tanguay, President and Chief
Executive Officer of Theratechnologies.
The preclinical phase for TH1173 is now completed. Results,
including those from seven-day and 28-day toxicology trials,
warrant the pursuit of the clinical stage development at the
appropriate time.
TH1173 is unpartnered and wholly-owned by Theratechnologies.
About Theratechnologies
Theratechnologies (TSX:TH)(NASDAQ:THER) is a biopharmaceutical
company that specializes in innovative therapeutic peptide
products, with an emphasis on growth-hormone releasing factor
peptides. Further information about Theratechnologies is available
on the Company's website at www.theratech.com, on SEDAR at
www.sedar.com and on the Securities and Exchange Commission's
website at www.sec.gov.
Forward-Looking Information
This press release contains certain statements that are
considered "forward-looking information" within the meaning of
applicable securities legislation, which statements may contain
such words as "may", "would", "could", "will", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions. This forward-looking information includes, but is not
limited to, information regarding the term of our patent, our
capacity to grow our revenues, the medical potential of TH1173, the
exploration of partnerships and licensing opportunities for TH1173
in certain territories and the pursuit of the clinical development
of TH1173 at the appropriate time.
Forward-looking information is based upon a number of
assumptions and is subject to a number of risks and uncertainties,
many of which are beyond Theratechnologies' control that could
cause actual results to differ materially from those that are
disclosed in or implied by such forward-looking information. These
assumptions include, but are not limited to, the fact that we will
be successful in defending the validity and enforceability of our
patent in the event it is challenged by a third party, that
tesamorelin for the treatment of excess abdominal fat in
HIV-infected patients with lipodystrophy will be approved, and,
once approved, accepted by the marketplace, in jurisdictions where
marketing authorization applications are pending, that we will
succeed in resubmitting a marketing authorization application (MAA)
for tesamorelin in Europe and that the MAA will be approved by
European regulatory authorities, that we will have the human and
financial resources, skills and know-how to pursue the development
of TH1173 and that results from such research will be positive and
allow us to continue the development of TH1173, and that third
parties will be interested in entering into partnership or
licensing agreements for TH1173 on commercial terms acceptable to
us. These risks and uncertainties include, but are not limited to,
the risk that we are unable to successfully defend the validity and
enforceability of our patent in the event it is challenged by a
third party, the risk that some or all of the pending marketing
authorization applications for tesamorelin are not approved or
that, if approved, the marketplace in the jurisdictions where
approval is obtained do not accept the product, the risk that we
are unable to resubmit an MAA for tesamorelin in Europe, the risk
that we do not have, or lose, the necessary resources, skills and
know-how to pursue the development of TH1173 or that results from
further research on TH1173 do not warrant the pursuit of further
development, and the risk that no third party is interested in
entering into partnership or licensing agreements with us regarding
TH1173 or that the terms of such agreements are not commercially
acceptable to us.
Theratechnologies refers potential investors to the "Risks
Factors" section of its Annual Information Form (AIF) dated
February 27, 2012. The AIF is available at www.sedar.com and at
www.sec.gov under Theratechnologies' public filings. The reader is
cautioned to consider these and other risks and uncertainties
carefully and not to put undue reliance on forward-looking
statements. Forward-looking information reflects current
expectations regarding future events and speaks only as of the date
of this press release and represents Theratechnologies'
expectations as of that date.
Theratechnologies undertakes no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise, except as may be required by applicable law.
Contacts: Denis Boucher NATIONAL Public Relations
514-843-2393
Therasense (NASDAQ:THER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Therasense (NASDAQ:THER)
Historical Stock Chart
From Jul 2023 to Jul 2024